CASIF CASI Pharmaceuticals, Inc. Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1962738 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-15.8%
TTM net income YoY-45.6%
TTM EPS YoY-26.7%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin-138.8%
Net margin-137.6%
FCF margin-103.2%
EBITDA margin-134.3%
Returns
ROE-301.8%
ROA-60.9%
ROIC (approx.)-435.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets96.6%
Debt / equity0.00x
Current ratio1.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.71M | $28.54M |
| Cost of revenue | $10.64M | $17.39M |
| Gross profit | $10.08M | $11.15M |
| R&D expense | $6.31M | $8.92M |
| SG&A expense | $28.27M | $23.58M |
| Operating income | -$45.01M | -$39.62M |
| Pretax income | -$45.87M | -$38.07M |
| Income tax | — | $0 |
| Net income | -$48.06M | -$39.26M |
| EBITDA | -$43.81M | -$38.32M |
| EPS (basic) | -2.59 | -2.56 |
| EPS (diluted) | -2.59 | -2.56 |
| Weighted avg. shares (diluted) | 18.54M | 15.34M |
| Balance sheet | ||
| Cash & equivalents | $5.63M | $13.47M |
| Receivables | $4.09M | $15.35M |
| Inventory | $1.60M | $5.25M |
| Current assets | $13.46M | $39.58M |
| PP&E, net | $6.97M | $7.87M |
| Intangibles | $221,000 | $238,000 |
| Total assets | $25.65M | $53.67M |
| Current liabilities | $49.67M | $36.45M |
| Short-term debt | $19.19M | $18.39M |
| Total liabilities | $62.93M | $51.82M |
| Shareholders' equity | -$37.28M | $1.85M |
| Shares outstanding | 20.56M | 15.49M |
| Cash flow statement | ||
| Operating cash flow | -$20.75M | -$29.22M |
| Capital expenditure | $16,000 | $223,000 |
| Free cash flow | -$20.77M | -$29.45M |
| Investing cash flow | $951,000 | $11.24M |
| Financing cash flow | $11.25M | $15.43M |
| Depreciation & amortization | $1.20M | $1.30M |
| Stock-based compensation | $2.99M | $1.31M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.